APPNAppian Corporation
Appian Corporation (APPN) sells application software focused on process automation and AI-driven workflow orchestration. The next catalyst is Feb 9, 2027 — Q4 2026 Earnings Release, which will test the company’s ability to deliver revenue growth and margin stability amid a competitive and capital-efficient market.
- Revenue grew 17.8% YoY to $827.07M, but net income remains negative at -$12.82M.
- The company has a negative net margin of -1.5% and a debt-to-equity ratio of -5.33x.
- Shareholders’ equity is -$46.99M, reflecting ongoing capital burn.
The Read
Appian's stock historically showed mixed reactions to catalysts, with a median absolute move of ~14%.
The schedule
- Tue9Feb
The earnings release will test the company's ability to deliver on its guidance and demonstrate progress in AI integration and cloud adoption, which differs from the last print where the focus was on cost management.
- Thu6May
The release will test the company's ability to maintain momentum in AI-driven product adoption and cloud services, which is a critical shift from the last print where the focus was on cost control.
- Thu29Jul
The release will test the company's ability to scale AI integration and cloud services, with a focus on revenue growth and margin expansion, which is a shift from the last print where the emphasis was on cost management.
- Thu21Oct
The release will test the company's ability to sustain AI integration and cloud growth, with a focus on long-term revenue and margin trends, which is a shift from the last print where the emphasis was on cost control.
Past
- Sat10Oct
Actual outcome: Bull · $51.94 at outcome
APPN experienced a significant short-term price increase likely driven by positive clinical trial results, which signaled strong efficacy or progress in its therapeutic development. The move suggests the data may have exceeded expectations, improving investor sentiment and positioning the stock for further gains. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +28.9% from 2026-10-07 to 2026-10-21 (~2.1σ vs typical 10d vol). Target date 2026-10-20 reached; move through 2026-10-21 observed. Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-22: +32.5% from 2026-10-08 (~2.4σ). Target date 2026-10-20 reached; move through 2026-10-22 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-23: +30.6% from 2026-10-09 (~2.2σ). Target date 2026-10-20 reached; move through 2026-10-23 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-28: +35.1% from 2026-10-14 (~2.6σ). Target date 2026-10-20 reached; move through 2026-10-28 observed.
APPN experienced a significant short-term price increase likely driven by positive clinical trial results, which signaled strong efficacy or progress in its therapeutic development. The move suggests the data may have exceeded expectations, improving investor sentiment and positioning the stock for further gains. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +28.9% from 2026-10-07 to 2026-10-21 (~2.1σ vs typical 10d vol). Target date 2026-10-20 reached; move through 2026-10-21 observed. Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-22: +32.5% from 2026-10-08 (~2.4σ). Target date 2026-10-20 reached; move through 2026-10-22 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-23: +30.6% from 2026-10-09 (~2.2σ). Target date 2026-10-20 reached; move through 2026-10-23 observed. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-28: +35.1% from 2026-10-14 (~2.6σ). Target date 2026-10-20 reached; move through 2026-10-28 observed.
- Tue15Sep
Actual outcome: Bull · $37.96 at outcome
The stock surged past the bull target following the Agent Studio Commercial Adoption Update, driven by strong commercial traction and positive momentum in converting pipeline into revenue. The update signaled progress in overcoming macro IT budget constraints, reinforcing investor confidence in the long-term growth trajectory of Appian's platform.
Critical mid-quarter industry window assessing the timeline for Appian's Agent Studio to convert pipeline into recognized revenue against macro IT budget constraints, entering at $21.50.
- Thu13Aug
Actual outcome: Bear · $38.42 at outcome
The company reported an EPS actual of -0.08, matching the estimate, but guidance signaled margin compression and weaker-than-expected revenue growth, undermining investor confidence. Despite a 3.9% price rise from the event date, the stock fell below the bear floor as concerns over long-term profitability and operational challenges overshadowed the neutral earnings report.
The earnings release will test whether the company can deliver better-than-expected guidance and margin expansion, differing from the last print where revenue growth was flat despite a positive surprise.
- Thu14May
Actual outcome: Bear · $21.37 at outcome
Appian's Investor Day featured an $825 million mid-term revenue goal, an expanded share buyback program, and a focus on reliable AI in enterprise workflows. Although these strategic updates and subsequent insider buying drove an 11.2% rally following the event, the stock still closed at $21.37, remaining below the $22.00 bear floor. The positive momentum from the presentation was ultimately insufficient to fully offset the heavy downward pressure from the 19% plunge that followed its Q1 earnings release earlier in the month.
Market will scrutinize Q2 cloud subscription momentum and potential mid-term financial goal expansions, evaluating whether recent multiple compressions represent a bottom.
- Thu7May
Actual outcome: Bear · $19.22 at outcome
Despite Appian beating Q1 estimates—highlighted by a 25% year-over-year jump in cloud subscription revenue—and raising its full-year outlook, the stock plunged over 17%. The severe sell-off despite strong headline numbers was likely driven by broader pressures on software multiples and investor concerns over the high hidden costs of AI integration, which the CEO notably flagged as the 'elephant under the rug' shortly after the release.
- Tue5May
Actual outcome: Bear · $19.19 at outcome
At the Appian World conference, the company showcased new capabilities in agentic automation and AI-assisted spec-driven development to transform complex workflows. However, these product and roadmap updates lacked the concrete financial metrics or enterprise adoption proof points needed to drive a significant breakout. As a result, the stock remained flat, trading between the bull and bear targets as the market awaits further evidence of AI-driven growth.
- Thu19Feb
Actual outcome: Bear · $25.14 at outcome
Appian initially surged after beating Q4 estimates and issuing aggressive 2026 guidance driven by its new 'Agent Studio' AI platform. However, the stock failed to sustain these gains and fell below the bear floor by the run date, as significant institutional selling and broader market skepticism regarding its long-term competitive moat in the low-code AI space outweighed the positive headline results.